These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 17206462)

  • 1. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.
    Vedder AC; Linthorst GE; van Breemen MJ; Groener JE; Bemelman FJ; Strijland A; Mannens MM; Aerts JM; Hollak CE
    J Inherit Metab Dis; 2007 Feb; 30(1):68-78. PubMed ID: 17206462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.
    Gupta S; Ries M; Kotsopoulos S; Schiffmann R
    Medicine (Baltimore); 2005 Sep; 84(5):261-268. PubMed ID: 16148726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early therapeutic intervention in females with Fabry disease?
    Hughes DA
    Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation.
    Lavalle L; Thomas AS; Beaton B; Ebrahim H; Reed M; Ramaswami U; Elliott P; Mehta AB; Hughes DA
    PLoS One; 2018; 13(4):e0193550. PubMed ID: 29621274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.
    Wijburg FA; Bénichou B; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini C; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymańska A; Ramaswami U
    PLoS One; 2015; 10(5):e0124987. PubMed ID: 25955246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy.
    Gaggl M; Lajic N; Heinze G; Voigtländer T; Sunder-Plassmann R; Paschke E; Fauler G; Sunder-Plassmann G; Mundigler G
    Int J Med Sci; 2016; 13(5):340-6. PubMed ID: 27226774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
    Auray-Blais C; Blais CM; Ramaswami U; Boutin M; Germain DP; Dyack S; Bodamer O; Pintos-Morell G; Clarke JT; Bichet DG; Warnock DG; Echevarria L; West ML; Lavoie P
    Clin Chim Acta; 2015 Jan; 438():195-204. PubMed ID: 25149322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease.
    Moura AP; Hammerschmidt T; Deon M; Giugliani R; Vargas CR
    Clin Chim Acta; 2018 Mar; 478():62-67. PubMed ID: 29274327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of patients with Fabry disease in Argentina].
    AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
    Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients.
    Boutin M; Menkovic I; Martineau T; Vaillancourt-Lavigueur V; Toupin A; Auray-Blais C
    Anal Chem; 2017 Dec; 89(24):13382-13390. PubMed ID: 29099167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.
    Schiffmann R; Forni S; Swift C; Brignol N; Wu X; Lockhart DJ; Blankenship D; Wang X; Grayburn PA; Taylor MR; Lowes BD; Fuller M; Benjamin ER; Sweetman L
    J Am Heart Assoc; 2014 Feb; 3(1):e000394. PubMed ID: 24496231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
    Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
    Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry.
    Lavoie P; Boutin M; Auray-Blais C
    Anal Chem; 2013 Feb; 85(3):1743-52. PubMed ID: 23248976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients.
    Heywood WE; Doykov I; Spiewak J; Hallqvist J; Mills K; Nowak A
    Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2726-2735. PubMed ID: 31319156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contribution of the measurement of globotriaosylceramide in urine to the diagnosis and follow-up of Fabry disease].
    Piraud M; Maire I; Froissart R
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S270-4. PubMed ID: 21211678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
    Wilcox WR; Oliveira JP; Hopkin RJ; Ortiz A; Banikazemi M; Feldt-Rasmussen U; Sims K; Waldek S; Pastores GM; Lee P; Eng CM; Marodi L; Stanford KE; Breunig F; Wanner C; Warnock DG; Lemay RM; Germain DP;
    Mol Genet Metab; 2008 Feb; 93(2):112-28. PubMed ID: 18037317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb
    Auray-Blais C; Lavoie P; Boutin M; Abaoui M
    Curr Protoc Hum Genet; 2017 Apr; 93():17.26.1-17.26.12. PubMed ID: 28384397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease.
    Gaggl M; Hofer M; Weidner S; Kleinert J; Fauler G; Wallner M; Kotanko P; Paschke E; Sunder-Plassmann G
    J Nephrol; 2015 Dec; 28(6):679-89. PubMed ID: 25857295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease.
    Apelland T; Gude E; Strøm EH; Gullestad L; Eiklid KL; Månsson JE; Reinholt FP; Houge G; Dahl CP; Almaas VM; Heiberg A
    Heart; 2014 Nov; 100(22):1793-8. PubMed ID: 25031264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.